



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY

Predictors of gait impairment in Parkinson's disease

Thesis

Submitted for Partial Fulfillment of Master Degree in
Neuropsychiatry

By

Engy Nady Sadik

MB, BChAin Shams University

Under Supervision of

Prof. Dr. Ali Soliman Ali Shalash

Professor of Neurology

Faculty of Medicine - Ain Shams University

Dr. Hossam-eldin Mahmoud Afify

Lecturer of Neurology

Faculty of Medicine - Ain Shams University

Dr. Eman Hamed AbdEldayem

Lecturer of Neurology

Faculty of Medicine - Ain Shams University

Faculty of Medicine

Ain Shams University

2020

Acknowledgments

*First and foremost, I feel always indebted and grateful to **Allah** for giving me the will and the strength to complete this study.*

*I wish to express my deep appreciation and sincere gratitude to **Prof. Dr. Ali Soliman Ali Shalash**, Professor of Neurology and Psychiatry, Ain Shams University, for his close supervision, valuable instructions, continuous help, patience, advices and guidance. He has generously devoted much of his time and effort for planning and supervision of this study. It was a great honor to me to work under his direct supervision*

*I wish to express my great thanks and gratitude to **Dr. Hossam-eldni Afify**, Lecturer of Neurology and Psychiatry, Ain Shams University, for her kind supervision, indispensable advice and great help in this work,*

*I wish to express my great thanks and gratitude to **Dr. Dr. Eman Hamed**, Lecturer of neurology and Psychiatry, Ain Shams University, for his kind supervision, indispensable advice and great help in this work,*

Last and not least, I want to thank all my family, my colleagues, for their valuable help and support.

Finally I would present all my appreciations to my patients, without them, this work could not have been completed.

 **Engy Nady Sadik**

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations	i
List of Tables	iii
List of Figures	vi
List of Appendices	v
Introduction	1
Aim of the Work	5
Review of Literature	
Parkinson's disease motor and non-motor symptoms.....	6
Gait dysfunction in Parkinson's disease	24
Predictors of gait impairment in PD	45
Patients and Methods	56
Results.....	67
Discussion	103
Conclusion	111
Limitations and Recommendations	112
Summary	113
References.....	116
Appendices	I
Arabic Summary.....	—

List of Abbreviations

Abbr.	Full-term
AD	: Alzheimer's disease
BBS	: Berg Balance Scale
BDI	: Beck depression inventory
CI	: Cognitive impairment
CMA	: Chaperone-mediated autophagy
CNS	: Central nervous system
ChE-I	: Cholinesterase inhibitors
CSVDs	: Cerebral small vessel diseases
DBS	: Deep brain stimulation
DTI	: Diffusion tensor imaging
FOG	: Freezing of gait
FMRI	: Functional magnetic resonance imaging
GPI	: Globus pallidus internus
H & Y	: Hoehn and Yahr
LM	: Logical memory
MCI	: Mild cognitive impairment
MDS	: Movement Disorder Society
MDS-UPDRS	: Movement Disorders Society-Unified Parkinson's Disease Rating Scale
M-EDL	: Motor Aspects of Experiences of Daily Living
MLR	: Mesencephalic locomotor region
MMSE	: Mini mental state examination
MPTP	: 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
MRI	: Magnetic resonance imaging
N-FOG	: New freezing of gait questionnaire
NM-EDL	: Non-Motor Aspects of Experiences of Daily Living
NMS	: Non-motor symptoms
NMSS	: Non-motor symptoms scale

PD	: Parkinson's disease
PDD	: PD with dementia
PET	: positron emission tomography
PIGD	: Postural instability and gait disturbance
PPNd	: dorsal Pedunculopontine nucleus
QOL	: Quality of life
REM	: Rapid eye movement
SNr	: Substantianigra pars reticularis
STN	: Sub-thalamic nucleus
TDCS	: Transcranial direct current stimulation
TMS	: Transcranial magnetic stimulation
UPDRS	: Unified Parkinson's Disease Rating Scale
UPS	: Ubiquitin-proteasome system
VPA	: Verbal Paired Associates
WCST	: Wisconsin card sorting test
WMH	: White matter hyperintensities
WMS	: Wechsler Memory Scale

List of Tables

Table No.	Title	Page No.
Table (1):	NMS of PD	15
Table (2):	Assessment of walking in PD.....	34
Table (3):	Description of studies evaluating medication effects (other than levodopa) on gait in PD.....	41
Table (4):	Average/fast walking speed m/s according to age.....	61
Table (5):	Normative Reference values	62
Table (6):	Scoring of MMSE:	62
Table (7):	Demographics of the PD patients involved in the study:	67
Table (8):	Level of education, family history, functioning and risk factors of the patients involved in the study:.....	68
Table (9):	Motor scales and NMSSs involved in the study	69
Table (10):	Hoehn and Yahr staging scale:.....	70
Table (11):	Descriptive data of gait assessment scales:	71
Table (12):	Cognitive assessment scales:.....	72
Table (13):	Percentage of MCI, dementia, and normal cognition according to MMSE.....	73
Table (14):	Radiological findings of recruited patients:	74

Table (15):	Comparison between patients with no/slight gait Impairment & patients with prominent gait impairment as regards demographic & clinical data:.....	76
Table (16):	Comparison between patients with no/slight gait Impairment & patients with prominent gait impairment as regards other demographic & clinical data	77
Table (17):	Comparison between Patients with no/slight gait Impairment & Patients with prominent gait impairment as regard motor and NMSSs:.....	79
Table (18):	Comparison between Patients with no/slight gait Impairment & Patients with prominent gait impairment as regard cognitive scales:	81
Table (19):	Comparison between Patients with no/slight gait impairment & Patients with prominent gait impairment as regard gait assessment scales:.....	83
Table (20):	Comparison between patients with no/slight gait impairment & patients with prominent gait impairment as regard radiological scales:	84
Table (21):	Comparison between pt with no/slight FOG & pt with prominent FOG as regards demographic & clinical data:.....	86
Table (22):	Comparison between patients with no/slight FOG & patients with prominent FOG as regards other clinical data:	87

Table (23):	Comparison between patients with no/slight FOG & patients with prominent FOG as regards motor and NMSSs:	89
Table (24):	Comparison between patients with no/slight FOG & patients with prominent FOG as regards cognitive assessment scales	90
Table (25):	Comparison between patients with no/slight FOG & patients with prominent FOG as regards gait assessment scales.....	91
Table (26):	Comparison between patients with no/slight FOG & patients with prominent FOG as regards radiological scales	92
Table (27):	Comparison of CI between patients with no/slight FOG & patients with prominent FOG as regards MMSE	93
Table (28):	Correlation between gait assessment scales and clinical characteristics:	94
Table (29):	Correlation between gait assessment scales and (motor and NMSSs)	97
Table (30):	Correlation between gait assessment scales and cognitive assessment scales:	99
Table (31):	Correlation between gait assessment scales and radiological findings:	100
Table (32):	Multiple regression analysis	102

List of Figures

Figure No.	Title	Page No.
Figure (1):	Pathogenesis of PD	10
Figure (2):	MDS clinical diagnostic criteria of PD.....	12
Figure (3):	The basal ganglia-thalamo-cortical pathway.....	27
Figure (4):	Hoehn and Yahr staging scale	70
Figure (5):	Percentage of MCI, mild dementia, moderate dementia and normal cognition according to MMSE.....	73
Figure (6):	MMSE and DOI.....	82
Figure (7):	Comparison between patients with no/slight FOG & patients with prominent FOG as regards PDQ-39, WCST, Wechsler test, MMSE, DOI.....	92
Figure (8):	Correlation between gait assessment scales and clinical characteristics.	95
Figure (9):	Correlation between gait assessment scales and radiological findings.....	101

Introduction

Parkinson's disease (PD) is the most common movement disorder besides essential tremor and the second most common neurodegenerative disease (**Tanner et al., 2000**). Egypt has higher prevalence of PD about 35 in 100000 as was studied previously (**Khedr et al., 2015**).

The prevalence of PD in industrialized countries is generally estimated at 0.3% of the entire population and about 1% in people over 60 years of age (**DeLau and Breteler, 2006**). The prevalence increases with advancing age both for men and women ages (**De Rijk et al., 1997**). In Europe, the prevalence at ages 85–89 has been reported as 3.5% (**Clarke and Moore, 2007**).

Braak et al. (2003) have mapped PD into six neuropathological stages. In the pre-symptomatic stages of the disease (stages 1–2), the inclusion bodies are confined to the medulla oblongata/pontine tegmentum and olfactory bulb/ anterior olfactory nucleus. With progression of the disease, substantia nigra and other nuclei of the midbrain and forebrain become affected (stages 3–4). It has been suggested that patients develop clinical symptoms of the disease at this stage. In the end stage (stage 5–6), the process enters the neocortex with a wide variety of clinical manifestations (**Braak et al., 2004**).

Gait is a learned, complex and almost automatic task with limited involvement of higher cognitive control in healthy individuals till old age (**Holtzer et al., 2006**). These automatic and rhythmic motor activity patterns are generated by spinal networks of motor neurons and interneurons, also called the "central pattern generators" (**Dietz, 2003**). The activity of these spinal networks is modulated and initiated by the basal ganglia and the brainstem nuclei (**Pahapill & Lozano, 2000**). The basal ganglia and their two-way connections with cortical regions and cerebellum play a central role in movement initiation (**Yogev-Seligman et al., 2008**).

Gait difficulties are one of the first problems reported in people with PD, indicating the onset of disability (**Shulman et al., 2008**). Parkinsonian gait is often slow and characterized by short shuffling steps. Such problems are often accompanied by falling, which occurs in 40–70% of patients with PD (**Pickering et al., 2007**).

Understanding gait difficulties and developing criteria to identify people with PD who are at risk for falling are crucial to interrupt this devastating cycle of falls and injuries (**Bloem et al., 2004**).

Freezing of gait (FOG) is a disabling gait disorder defined as a “brief, episodic absence or marked reduction of forward progression of the feet despite the intention to walk” (**Nutt et al., 2011**).

Longer disease duration and greater disease severity often increase the likelihood of developing FOG (**Giladi et al., 2001**). FOG is less efficiently improved with dopaminergic medication (**Espay et al., 2012**), so early risk identification of FOG may improve its treatment in the near future (**Rascol et al., 2011**).

Cognitive impairment (CI) is a common non-motor complication of PD and is associated with significant disability for patients and burden for caregivers. Similar to motor symptoms, the characteristics of CI in PD can be quite variable, both in terms of what cognitive domains are impaired and the timing of onset and rate of progression (**Aarsland et al., 2005**).

PD with dementia (PDD) has a cross-sectional prevalence of approximately 30% and a life-long risk of up to 80% (**Hely et al., 2008**).

Research suggests an association between global cognition and postural instability/gait disturbance (PIGD) in PD, but the relationship between specific cognitive domains and PIGD symptoms is not clear (**Kelly et al., 2015**).

Moreover, fall risk factors among patients with PD include disease severity, motor function, and level of mobility (**Kerr et al., 2010**); studies also identified cognitive impairment as an independent contributing factor (**Allcock et al., 2009**).